AM-Pharma
PrivateLast Round
Series E
Extension
Mar 31, 2020
Total Funding Raised
$321.53M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AM-Pharma operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was a Series E Extension round in March 2020.
AM-Pharma is a biopharmaceutical company developing proprietary recombinant human alkaline phosphatase therapeutics for the treatment of severe medical conditions such as acute kidney injury, inflammatory bowel disease, and hypophosphatasia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AM-Pharma Comparables
Compare AM-Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alloksys Life Sciences B.V. | 86% | |
| Guard Therapeutics International AB | 86% | |
| Renibus Therapeutics | 85% |
For institutional investors. Book with your work email.
AM-Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E Extension | Mar 31, 2020 | ||||
| Series E | Jul 16, 2019 | ||||
| Corporate Funding | May 11, 2015 | ||||
| VC Round | Sep 11, 2014 | ||||
| Series D | Sep 13, 2011 | ||||
Debt | Mar 19, 2009 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AM-Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B, Series C, Series E, Series D |
| EQT Life Sciences | Series E Extension, Series E |
| Idinvest Partners | VC Round, Series E, Series E Extension, Series D |
| Forbion | Series C, Series E, Series E Extension, Series D |
| BB Biotech | VC Round, Series D |
| Andera Partners | Series E Extension, Series E |
| Ysios Capital | VC Round, Series E, Series E Extension, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 59% MoM.
- Oct 2, 2025
Developing ilofotase alfa for AKI and HPP indications.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- identified_as_competitor_ofOct 20, 2026
AM-Pharma's investigational ilofotase alfa could take on AstraZeneca's Strensiq in treating the rare bone disease hypophosphatasia.
For institutional investors. Book with your work email.
AM-Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AM-Pharma's valuation, stock price, and market status.
Is AM-Pharma a public or private company?
AM-Pharma is a private company.
What is the current stock price of AM-Pharma?
AM-Pharma is a private company, so its shares have no public market price. Caplight tracks AM-Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AM-Pharma worth (valuation)?
Valuation information for AM-Pharma is not publicly available.
Can I buy AM-Pharma stock?
AM-Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AM-Pharma's last funding round?
AM-Pharma's most recent funding round was Series E Extension on March 31, 2020.
Who are the main investors in AM-Pharma?
Key investors in AM-Pharma include Forbion Capital Partners, EQT Life Sciences, Andera Partners, Ysios Capital, Blue Owl Capital.
Will AM-Pharma IPO soon?
No public IPO plans have been announced for AM-Pharma.
How can I track AM-Pharma secondary market activity?
Caplight tracks bids, offers, and trades in AM-Pharma's shares on secondary markets.